On August 5th, Gelunhui reported that Northeast Pharmaceutical Group (000597.SZ) and Mr. Zhang Rong have signed a "Equity Acquisition Framework Agreement" and plan to acquire 70% equity of Peking Dingcheng Peptide Source Biotechnology Co., Ltd. (hereinafter referred to as "Dingcheng Peptide Source").
According to the announcement, Dingcheng Peptide Source has formed a complete technical platform and product transformation system for TCR-T and CAR-T cell therapy products, and has developed more than 10 cell therapy products targeting KRAS mutation, EGFRvIII, AFP, Claudin18.2 and other targets for pancreatic cancer, colorectal cancer, gastric cancer, liver cancer and glioma, as well as innovative CAR-T and other TCR protein drugs.
In addition, Dingcheng Peptide Source plans to use DCTY0801 injection, a CAR-T cell therapy product for glioblastoma, which has obtained orphan drug qualification certification from the US FDA in May 2023. The product is currently undergoing IND applications in both China and the United States.
